View Post

Endoxifen Shows Promise in Treating Breast Cancer in Australian Trial, Development in the US to Accelerate

In Clinical Trials by Barbara Jacoby

By: Ryan McDonald From: curetoday.com Results of a trial assessing endoxifen in patients with breast cancer in Australia were positive enough for the manufacturer to stop the trial before it was scheduled to be completed. The drug’s manufacturer will now accelerate its development in the U.S. Treatment with oral endoxifen during the “window of opportunity” between breast cancer diagnosis and …

View Post

Examining resistance to breast cancer treatments

In Clinical Trials by Barbara Jacoby

By: Molly Chiu From: bcm.edu The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment. Researchers at the Lester …

View Post

Identification of Tamoxifen Resistance Markers Can Play Role in Breast Cancer Treatment Planning

In Clinical Trials by Barbara Jacoby

By: Rutgers Cancer Institute of New Jersey From: newswise.com One common challenge of cancer therapy is when cancer cells don’t respond to a drug that is usually able to kill or weaken them, known as treatment resistance. Tamoxifen is a drug that blocks the activity of estrogen in the breast, commonly used to treat patients with estrogen-receptor (ER) positive breast cancer. In …

View Post

New discovery in breast cancer treatment

In In The News by Barbara Jacoby

Source: University of Adelaide From: eurekalert.org Researchers at the University of Adelaide have found new evidence about the positive role of androgens in breast cancer treatment with immediate implications for women with estrogen receptor-driven metastatic disease. Published today in Nature Medicine, the international study conducted in collaboration with the Garvan Institute of Medical Research, looked at the role of androgens …

View Post

Yoga Therapy and Qigong for the Self-management of Pain among ER+ Breast Cancer Survivors

In In The News by Barbara Jacoby

Dr. Judi Fouladbakhsh, a nurse researcher at Oakland University (Rochester, Michigan) is seeking participants for her study exploring self-treatment of pain among women who have had Estrogen-receptor positive (ER+) breast cancer (age 21+) who report pain. Participants will receive 12-weeks of free (one-hour, one time per week) classes in Qigong/Taiji offered online by the Center for Taiji Studies. Participants will …

View Post

Educational Session explores advances in treating ER positive breast cancer

In In The News by Barbara Jacoby

From: sabcsmeetingnews.org Estrogen receptor positive (ER+) breast cancers may represent the single largest unmet clinical need in the field. ER+ breast cancer, also called luminal breast cancer, was once considered the default type of breast cancer, said David A. Cameron, MD, MSc. “Luminal breast cancer is the commonest type of breast cancer we see worldwide, about three-quarters of all breast …

View Post

Expert Reviews Novel Strategies in the Pipeline for the Treatment of ER-Positive Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Audrey Sternberg From: targetedonc.com Recent acceleration in the introduction of new regimens for the treatment of estrogen receptor (ER)–positive breast cancer has led to significant survival enhancement, but questions remain regarding how patients should be stratified following disease progression with these therapies.1 “In the last 7 or 8 years, we’ve seen the CDK4/6 inhibitors added to endocrine therapy and …

View Post

Translational Research in Oncology (TRIO) Enrolls First Patient in Early Breast Cancer Phase 2 Trial

In Clinical Trials by Barbara Jacoby

Source: Translational Research in Oncology From: globenewswire.com Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of the first patient in a Phase 2 randomized, multi-center, open-label clinical trial of GDC-9545 sponsored by F. Hoffmann-La Roche. GDC-9545 is a selective estrogen receptor degrader (SERD) that was shown to be well tolerated with encouraging tumour activity …

View Post

Interview: The Development of Sermonix’ Lasofoxifene in Advanced or Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Editorial Team From: oncozine.com In 2014 David Portman, MD, a leading clinical researcher and expert in women’s health, sexual medicine and menopause, and selective estrogen receptor modulators (SERM) founded Sermonix Pharmaceuticals, is a privately held biotechnology company focused on the development and commercialization of female-specific oncology products. With a precision medicine focus for bringing targeted oncology products through development, …

View Post

Phase 1 human trials suggest UIC-developed breast cancer drug is safe, effective

In Clinical Trials by Barbara Jacoby

By: University of Illinois at Chicago From: newswise.com A new type of breast cancer drug developed by researchers at the University of Illinois Chicago can help halt progression of disease and is not toxic, according to phase 1 clinical trials. The drug is specifically designed for women whose cancer has stopped responding to hormone therapy. The results are published in the journal Breast …